Carisma Therapeutics Financials
| CARM Stock | 0.85 0.01 1.19% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.14 | 5.0585 |
|
|
Investors should never underestimate Carisma Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Carisma Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Carisma Therapeutics.
Net Income |
|
Carisma | Select Account or Indicator |
Understanding current and past Carisma Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Carisma Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Carisma Therapeutics' assets may result in an increase in income on the income statement.
Carisma Therapeutics Stock Summary
Carisma Therapeutics competes with Cns Pharmaceuticals, ZyVersa Therapeutics, Immix Biopharma, Hepion Pharmaceuticals, and Zura Bio. Carisma Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US14216R1014 |
| CUSIP | 817763105 286221106 14216R101 |
| Location | Massachusetts; U.S.A |
| Business Address | 3675 Market Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.carismatx.com |
| Phone | 267 491 6422 |
Carisma Therapeutics Key Financial Ratios
| Return On Equity | -3.63 | ||||
| Operating Margin | (3.88) % | ||||
| Price To Sales | 1.76 X | ||||
| Revenue | 14.92 M | ||||
| EBITDA | (85.89 M) |
Carisma Therapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 114.4M | 58.5M | 35.4M | 72.2M | 89.6M | 65.7M | |
| Other Current Liab | 6.6M | 1.6M | 4.5M | 10.9M | 6.7M | 4.1M | |
| Net Debt | (48.1M) | (48.3M) | (25.9M) | 16.0M | (74.5M) | (70.8M) | |
| Retained Earnings | (293.5M) | (56.2M) | (97.0M) | (158.2M) | (245.1M) | (232.8M) | |
| Accounts Payable | 1.9M | 3.3M | 2.3M | 1.7M | 3.9M | 2.1M | |
| Cash | 48.1M | 51.8M | 28.6M | 24.2M | 77.6M | 81.5M | |
| Other Current Assets | 6.3M | 1.3M | 1.2M | 2.6M | 2.9M | 1.5M | |
| Total Liab | 141.1M | 8.3M | 9.4M | 101.3M | 63.0M | 47.8M | |
| Total Current Assets | 54.4M | 53.1M | 29.8M | 54.6M | 80.5M | 84.5M | |
| Common Stock | 77K | 107K | 140K | 199K | 40K | 56.4K |
Carisma Therapeutics Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (2.3M) | 44.8M | (23.2M) | (138.4M) | 53.4M | 56.1M | |
| Stock Based Compensation | 1.2M | 163K | 479K | 275K | 2.3M | 2.4M | |
| Free Cash Flow | (37.7M) | (27.5M) | (39.2M) | (12.2M) | (82.3M) | (78.2M) | |
| Change In Working Capital | (3.1M) | (453K) | 1.5M | 45.2M | (5.4M) | (5.2M) | |
| Begin Period Cash Flow | 50.4M | 7.0M | 51.8M | 162.6M | 24.2M | 37.6M | |
| Other Cashflows From Financing Activities | (136K) | 72.3M | 16.0M | (35.9M) | 32.2M | 33.9M | |
| Other Non Cash Items | 72.8M | 1.2M | 834K | (19.6M) | 6.0M | 6.5M | |
| Capital Expenditures | 136K | 440K | 1.9M | 4.7M | 1.1M | 810.6K | |
| Total Cash From Operating Activities | (37.5M) | (27.0M) | (37.3M) | (7.6M) | (81.2M) | (77.1M) | |
| Net Income | (107.5M) | (28.3M) | (40.8M) | (61.2M) | (86.9M) | (82.5M) | |
| Total Cash From Financing Activities | 35.4M | 72.3M | 16.0M | 35.8M | 62.2M | 35.2M | |
| End Period Cash Flow | 48.1M | 51.8M | 28.6M | 24.2M | 77.6M | 81.5M |
Carisma Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Carisma Therapeutics's current stock value. Our valuation model uses many indicators to compare Carisma Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Carisma Therapeutics competition to find correlations between indicators driving Carisma Therapeutics's intrinsic value. More Info.Carisma Therapeutics is rated below average in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, Carisma Therapeutics' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Carisma Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Carisma Therapeutics Systematic Risk
Carisma Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Carisma Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on Carisma Therapeutics correlated with the market. If Beta is less than 0 Carisma Therapeutics generally moves in the opposite direction as compared to the market. If Carisma Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Carisma Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Carisma Therapeutics is generally in the same direction as the market. If Beta > 1 Carisma Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Carisma Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Carisma Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Carisma Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Carisma Therapeutics December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Carisma Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Carisma Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Carisma Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Carisma Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Carisma Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.19) | |||
| Maximum Drawdown | 16.3 | |||
| Value At Risk | (6.38) | |||
| Potential Upside | 4.08 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.493 | Quarterly Revenue Growth (0.12) | Return On Assets (0.56) | Return On Equity (3.63) |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.